SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following reports that the company is planning a bid for eBay to transform into a major retail giant, sparking intense debate among community members over the financing and viability of such an ambitious acquisition. While retail investors are discussing potential short squeezes and aggressive corporate strategy, many participants remain skeptical of how the firm will bridge the gap between its current market capitalization and eBay's significantly larger valuation.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The community is actively debating the legitimacy of the MULN crypto token, with many users drawing parallels between its price action and the volatile history of its associated EV stock. Conversations are heavily polarized, featuring aggressive recruitment attempts from supporters hoping for a speculative pump alongside vocal detractors labeling the project a recurring scam.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following a Wall Street Journal report that GameStop is quietly building a stake in the company with potential takeover intentions. While the community is actively debating the feasibility and financial logic of such a massive acquisition, the news has sparked significant options activity and price volatility as traders speculate on the aggressive retail transformation strategy.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Fannie Mae (FNMA) is surging on massive volume as investors react to high-profile commentary labeling the stock as significantly undervalued, fueling intense speculation about a potential privatization and exit from government conservatorship. The community remains deeply divided, with bulls pointing to the potential for a massive historical IPO, while skeptics warn the sudden volatility reflects a coordinated pump-and-dump scheme rather than fundamental news.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing significant volatility and downward pressure as investors rotate into other sectors, despite strong fundamentals like high revenue growth and robust brand expansion. The community is actively debating the stock's disconnect from its growth narrative, with sentiment split between long-term holders accumulating at perceived support levels and bears concerned about channel inventory, commodity cost pressures, and a lack of immediate catalysts ahead of upcoming earnings.

WorldFinancial

WorldFinancial (WLFI) is currently trending as investors debate its long-term viability amid a contentious governance vote on token lockups, a controversial multi-million dollar investment from UAE-affiliated partners, and ongoing allegations of a 'pump and dump' scheme. While some in the community highlight the project's potential for institutional integration and supply shocks from token burns, others are actively exiting, citing concerns over management's lack of transparency and legal scrutiny surrounding the leadership's business dealings.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is seeing heightened market activity and community debate following a series of conflicting analyst updates, with some firms citing growth potential in international markets and retail offerings while others caution against valuation concerns and regulatory hurdles. Traders remain divided on the stock's direction, with discussions focusing on the company's long-term reliance on automated logistics and the impact of the evolving gig economy on order demand.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

$AIRCOIN is trending due to its community's focus on long-term conviction, highlighted by high on-chain token locking rates and a treasury-backed model designed to sustain momentum. Investors are actively discussing its potential for a major breakout, drawing comparisons to historical market performance and emphasizing the project's transparent, builder-focused culture.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is trending as investors react to preliminary quarterly results and the controversial proposal for shareholder authorization of future reverse stock splits. The community is actively divided, with many expressing frustration over persistent dilution and leadership concerns, while others highlight the potential of Tonmyas growing prescription numbers as a sign of long-term commercial momentum.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin (CRO) is sparking debate as investors weigh the potential for institutional growth from upcoming Cronos app launches and ETF filings against ongoing frustrations regarding supply dilution and stagnant price performance. The community is actively tracking these developments while simultaneously rotating interest into Cronos-based meme coins like crow with knife ($CAW) and Mistery ($MERY) in search of rapid upside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>LCID remains under pressure from production scale challenges and persistent operating losses.</li><li>SNGX plunged after an independent panel recommended stopping its late-stage HyBryte trial in cutaneous T-cell lymphoma.</li><li>SRAD shares came under pressure after&nbsp;swinging to a Q1&nbsp;loss per share of 0.02 euros despite revenue growth.</li></ul>Shares of Lucid Group, Soligenix and Sportradar Group slid to fresh 52-week lows on Tuesday, with broader market weakness adding to pressure from a failed trial, weak results, and demand issues.On Tuesday,&nbsp;<a href="https://stocktwits.com/symbol/LCID">LCID stock</a> slipped 1%, marking its fifth straight session of losses, while&nbsp;<a href="https://stocktwits.com/symbol/SNGX">SNGX</a> plunged 70% and&nbsp;<a href="https://stocktwits.com/symbol/SRAD">SRAD</a> fell 11%.<h2 class="st-heading-2">Demand And Losses Weigh On LCID</h2>LCID shares extended their decline amid rising concerns over production-scale challenges and persistent operating losses in a volatile EV-demand environment.The company previously projected first-quarter revenue of about $280 million to $284 million, along with an operating loss of $1 billion, while full-year production guidance of 25,000 to 27,000 vehicles came in below earlier expectations. Investors remain focused on the company’s premium Air sedan and Gravity SUV lineup, with its lower-priced midsize platform not expected to enter production until later in 2026.Lucid is also seeking shareholder approval for several proposals at its June 4 annual meeting, including an amendment to its 2021 stock incentive plan that would add 23.5 million shares to the equity pool to support compensation for incoming CEO Silvio Napoli.Support from its largest shareholder, Saudi Arabia’s Public Investment Fund (PIF), remains key to the company’s financing. The sovereign wealth fund recently invested $550 million through its affiliate, Ayar Third Investment Company, as part of a broader $1.05 billion capital infusion that also included funding tied to a vehicle supply agreement with Uber and its autonomous mobility partner, Nuro.<h2 class="st-heading-2">Trial Setback Sends SNGX Tumbling</h2>SNGX stock plunged after an independent safety review panel recommended stopping a late-stage clinical trial of its cancer treatment, HyBryte, early, saying the interim results showed the therapy was unlikely to work as intended in patients with cutaneous T-cell lymphoma, a type of skin cancer.&nbsp;CEO Christopher J. Schaber said the company will now review the full dataset and may engage with regulators, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), to figure out potential next steps.With $5.9 million in cash on hand, the company said it is also evaluating options, including possible merger opportunities and advancing Dusquetide for Behcet’s Disease after receiving orphan drug designation from the European Commission.<h2 class="st-heading-2">Bleak Earnings Pressure SRAD Shares</h2>SRAD shares also came under pressure after the company reported first-quarter results showing a swing to a loss, even as revenue increased from the previous year.The sports data company reported a Q1 loss per share of 0.02 euros, compared with a loss per share of 0.07 euros a year earlier, while revenue rose to 346.5 million euros from 311.2 million euros a year ago. However, the company reiterated its full-year outlook for revenue of 1.56-1.58 billion euros and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of 390-400 million euros.The earnings call was followed by a price-target cut from Canaccord Genuity to $28 from $34, still implying a 127% upside from current levels. The brokerage also maintained its ‘Buy’ rating on SRAD shares. Separately, a short position disclosed by Muddy Waters Research added to investor caution after the firm raised concerns about exposure to illegal betting markets.<h2 class="st-heading-2">How Do Retail Traders Feel About LCID, SNGX, SRAD?</h2>Despite their fresh 52-week lows, retail sentiment for LCID, SNGX and SRAD remained broadly positive on Stocktwits, with LCID marked “extremely bullish” on ‘high’ message volume, while sentiment for SNGX and SRAD was “bullish” amid ‘extremely high’ chatter.Over the past year, LCID is down 77%, SNGX is down 80%, and SRAD is down 45%.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/asts-stock-loses-orbit-ceo-pay-satellite-targets/cZBqnglRe3c">ASTS Stock Loses Orbit As Investors Get Cold Feet Over CEO Pay Tied To Satellite Targets&nbsp;</a>

Over the past year, LCID is down 77%, SNGX is down 80%, and SRAD is down 45%.

LCID, SNGX, SRAD Stock Hit 52-Week Lows Today: What's Driving The Selloff? 

On Tuesday, LCID stock slipped 1%, marking its fifth straight session of losses, while SNGX plunged 70% and SRAD fell 11%.

Equity

<ul class="summary-bullets"><li>The trial was evaluating HyBryte in a rare form of cancer with limited treatment options.</li><li>The company also plans to assess whether certain patient groups could still benefit from the therapy.</li><li>Last month, the European Commission granted orphan drug designation (ODD) to Soligenix’s Dusquetide for the treatment of Behçet’s Disease.</li></ul>Shares of Soligenix Inc. (SNGX) crashed more than 70% to a record low on Tuesday after the biotech firm said its late-stage trial to treat lymphoma suffered a severe blow after an independent committee recommended stopping the study due to a lack of effectiveness.<a href="https://stocktwits.com/symbol/SNGX">SNGX stock</a> recorded its biggest intraday loss in more than 14 years.<h2 class="st-heading-2">What Went Wrong?</h2>Soligenix said that an independent data monitoring committee recommended stopping the Phase 3 FLASH2 trial after an interim analysis showed the treatment was unlikely to be effective in patients with cutaneous T-cell lymphoma.The trial was evaluating HyBryte, a light-activated therapy, in a rare form of cancer with limited treatment options. Management said it will now review the full dataset to understand why the study fell short. The company also plans to assess whether certain patient groups could still benefit from the therapy.“We are obviously very disappointed with the unanticipated outcome of the study. Despite the fact that HyBryte demonstrated statistically significant reductions in CTCL lesions after 6 weeks treatment in the first FLASH study, a similar signal was not observed with 18 weeks of treatment in this study,” said Christopher J. Schaber, CEO of Soligenix.&nbsp;Depending on the findings, Soligenix said it may engage in discussions with regulators, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), to determine possible next steps.<h2 class="st-heading-2">Hopes Pinned On Behçet’s Disease Treatment</h2>Last month, the European Commission granted orphan drug designation (ODD) to Dusquetide for the treatment of Behçet’s Disease, following a positive recommendation from the EMA. Behçet’s Disease is a rare, chronic disorder that causes inflammation of blood vessels.The decision was supported by Phase 2a data showing the drug was effective and safe in patients. Orphan status in Europe gives the company up to 10 years of market exclusivity if the treatment is approved. The drug has already received orphan drug and fast track designations from the FDA.“With approximately $5.9 million of cash, we will evaluate all strategic options moving forward, including but not limited to merger and acquisition opportunities as well as the potential of advancing Dusquetide for the treatment of Behçet’s Disease, which demonstrated promising biological efficacy in a Phase 2 study last year using the intravenous formulation and has received orphan drug designation most recently from the EMA,” Schaber said.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Despite the massive sell-off, retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.The stock has sunk 69% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/bbby-stock-pares-gains-hits-200dma-wedbush-price-target/cZB8yzPRedW">BBBY Stock Pares Early Gains Driven By Strong Q1 Report – Why Is Wedbush Optimistic About The Company’s Turnaround Story?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

SNGX Stock Slumps To Record Low After Lymphoma Trial Fails – All Eyes Now On Behçet’s Disease Treatment

An independent committee recommended stopping Soligenix’s late-stage trial to treat lymphoma due to a lack of effectiveness.

Why Is Soligenix Stock Sinking Tuesday?

Soligenix ends Phase 3 FLASH2 study for HyBryte. CEO cites unanticipated results. See how this impacts SNGX and next steps.read more...

Dow Gains 150 Points; Coca-Cola Posts Upbeat Earnings

US stocks mixed with Dow up 150 pts. Dow up 0.27%, NASDAQ down 1.06%, S&P 500 down 0.52%. Energy shares up 1.7%. Coca-Cola beats earnings & raises guidance. Baiya Int'l up 126%, Nexera up 63...

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte in Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte in Treatment of Cutaneous T-Cell Lymphoma Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial...

Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach

By Christopher J. Schaber,&#160;chairman, president, and CEO,&#160;Soligenix; published via Clinical Leader&#160; Soligenix&#160;(NASDAQ: SNGX)&#160;is emphasizing&#160;the strategic importance of patient-centric drug development, as outlined by CEO Christopher J. Schaber in a Clinical Leader guest column, which explores how reformulating therapies can improve access, adherence, and real-world viability. Drawing on the company’s experience with SGX945, Schaber explains that [&#8230;]

Soligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

Recognition from global regulatory authorities can serve as a powerful validation of a therapy’s potential, particularly in the rare disease space where development challenges are significant and patient needs are urgent.&#160;Soligenix (NASDAQ: SNGX)&#160;has&#160;secured&#160;that type of validation, as the European Commission granted orphan drug designation to its investigational therapy SGX945 for the treatment of Behçet’s disease, [&#8230;]

Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results

Advancing clinical research while generating positive data is a critical combination in biotechnology, particularly when addressing diseases with limited treatment options.&#160;Soligenix (NASDAQ: SNGX)&#160;is demonstrating that momentum as it provides&#160; both an encouraging&#160;clinical update&#160;from its phase 3 FLASH2 study and positive comparative&#160;clinical results&#160;for its HyBryte therapy, reinforcing the company’s focus on developing innovative treatments for serious [&#8230;]

Positive Clinical Results from HyBryte Comparative Study Evaluating HyBryte Against Valchlor in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

Positive Clinical Results from HyBryte Comparative Study Evaluating HyBryte Against Valchlor in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy Positive Clinical Results...

Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results

Soligenix (NASDAQ: SNGX)&#160;reported 2025 results highlighting progress across its rare disease pipeline, including advancing its Phase 3 FLASH2 trial of HyBryte(TM) for cutaneous T-cell lymphoma with interim analysis expected in Q2 2026 and top-line results anticipated in the second half of the year. The company also noted regulatory momentum with orphan drug designation for dusquetide [&#8230;]

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

SNGX
Soligenix Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest SNGX News

SNGXSoligenix Inc